Patients with locally advanced prostate cancer(PCa) are thought to be at a significant risk of death from PCa or development of distant metastases. To improve the prognosis of those patients, a variety of clinical trials with adjuvant and/or neoadjuvant therapies have been performed. In this review, we described a benefit of integrating local and systemic therapies in the management of locally advanced PCa.